This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thauvin-Eliopoulos, C.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thauvin-Eliopoulos, C.
Right arrow Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1997, 1053-1057, Vol 41, No. 5
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta- lactamase-producing strain of Klebsiella pneumoniae

C Thauvin-Eliopoulos, MF Tripodi, RC Moellering Jr and GM Eliopoulos
Department of Medicine, Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

The in vivo activities of piperacillin-tazobactam and cefepime were compared with those of ticarcillin-clavulanate, ceftazidime, cefotaxime, and imipenem in a rat model of intra-abdominal abscess with a strain of Klebsiella pneumoniae elaborating an extended-spectrum beta- lactamase (TEM-26). With the exception of ceftazidime, all of the antimicrobial agents significantly reduced bacterial counts within abscesses at the end of therapy compared with those in untreated controls. Residual viable cell counts (mean +/- standard deviation in log10 CFU/gram) were as follows: control, 8.76 +/- 0.97; ceftazidime, 8.00 +/- 0.76; piperacillin-tazobactam, 3.87 +/- 1.72; ticarcillin- clavulanate, 3.74 +/- 1.34; cefepime, 3.15 +/- 1.19; cefotaxime, 2.61 +/- 0.77; imipenem, 2.41 +/- 0.93. Imipenem was more effective than either of the inhibitor combinations (P < 0.05). Cefotaxime was unexpectedly effective given its poor in vivo activity against this organism in our earlier studies, which used a different dose and total duration of therapy (L. B. Rice, J. D. C. Yao, K. Klimm, G. M. Eliopoulos, and R. C. Moellering, Jr., Antimicrob. Agents Chemother. 35:1243-1244, 1991). These observations suggest that the effectiveness of cephalosporins in the treatment of experimental infections caused by extended-spectrum beta-lactamase-producing K. pneumoniae may be highly dependent on dosing regimens, even for a specific organism and site of infection.


This article has been cited by other articles:

  • Zimhony, O., Chmelnitsky, I., Bardenstein, R., Goland, S., Hammer Muntz, O., Navon Venezia, S., Carmeli, Y. (2006). Endocarditis Caused by Extended-Spectrum-{beta}-Lactamase-Producing Klebsiella pneumoniae: Emergence of Resistance to Ciprofloxacin and Piperacillin-Tazobactam during Treatment despite Initial Susceptibility.. Antimicrob. Agents Chemother. 50: 3179-3182 [Abstract] [Full Text]  
  • Paterson, D. L., Bonomo, R. A. (2005). Extended-Spectrum {beta}-Lactamases: a Clinical Update. Clin. Microbiol. Rev. 18: 657-686 [Abstract] [Full Text]  
  • Kang, C.-I., Kim, S.-H., Park, W. B., Lee, K.-D., Kim, H.-B., Kim, E.-C., Oh, M.-D., Choe, K.-W. (2004). Bloodstream Infections Due to Extended-Spectrum {beta}-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Mortality and Treatment Outcome, with Special Emphasis on Antimicrobial Therapy. Antimicrob. Agents Chemother. 48: 4574-4581 [Abstract] [Full Text]  
  • LaPlante, K. L., Rybak, M. J. (2004). Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 48: 4665-4672 [Abstract] [Full Text]  
  • Kang, C.-I., Pai, H., Kim, S.-H., Kim, H.-B., Kim, E.-C., Oh, M.-d., Choe, K.-W. (2004). Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type {beta}-lactamase. J Antimicrob Chemother 54: 1130-1133 [Abstract] [Full Text]  
  • Maglio, D., Ong, C., Banevicius, M. A., Geng, Q., Nightingale, C. H., Nicolau, D. P. (2004). Determination of the In Vivo Pharmacodynamic Profile of Cefepime against Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli at Various Inocula. Antimicrob. Agents Chemother. 48: 1941-1947 [Abstract] [Full Text]  
  • Tumbarello, M., Citton, R., Spanu, T., Sanguinetti, M., Romano, L., Fadda, G., Cauda, R. (2004). ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. J Antimicrob Chemother 53: 277-282 [Abstract] [Full Text]  
  • Navon-Venezia, S., Hammer-Munz, O., Schwartz, D., Turner, D., Kuzmenko, B., Carmeli, Y. (2003). Occurrence and Phenotypic Characteristics of Extended-Spectrum {beta}-Lactamases among Members of the Family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and Evaluation of Diagnostic Tests. J. Clin. Microbiol. 41: 155-158 [Abstract] [Full Text]  
  • Leverstein-van Hall, M. A., Fluit, A. C., Paauw, A., Box, A. T. A., Brisse, S., Verhoef, J. (2002). Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactamases in Multiresistant Escherichia coli and Klebsiella spp.. J. Clin. Microbiol. 40: 3703-3711 [Abstract] [Full Text]  
  • Thomson, K. S., Moland, E. S. (2001). Cefepime, Piperacillin-Tazobactam, and the Inoculum Effect in Tests with Extended-Spectrum beta -Lactamase-Producing Enterobacteriaceae. Antimicrob. Agents Chemother. 45: 3548-3554 [Abstract] [Full Text]  
  • Paterson, D. L., Ko, W.-C., Von Gottberg, A., Casellas, J. M., Mulazimoglu, L., Klugman, K. P., Bonomo, R. A., Rice, L. B., McCormack, J. G., Yu, V. L. (2001). Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum {beta}-Lactamases: Implications for the Clinical Microbiology Laboratory. J. Clin. Microbiol. 39: 2206-2212 [Abstract] [Full Text]  
  • Szabó, D., Máthé, A., Filetóth, Z., Anderlik, P., Rókusz, L., Rozgonyi, F. (2001). In Vitro and In Vivo Activities of Amikacin, Cefepime, Amikacin plus Cefepime, and Imipenem against an SHV-5 Extended-Spectrum {beta}-Lactamase-Producing Klebsiella pneumoniae Strain. Antimicrob. Agents Chemother. 45: 1287-1291 [Abstract] [Full Text]  
  • Fung, H. B., Kuczynski, S., Finch, D. A., Ramos, L. (2001). Current Issues in Gram-Negative Resistance: Extended-Spectrum Beta-Lactamases and Inducible Beta-Lactamases. Journal of Pharmacy Practice 14: 6-17 [Abstract]  
  • Schumacher, H., Scheibel, J., Moller, J. K. (2000). Cross-resistance patterns among clinical isolates of Klebsiella pneumoniae with decreased susceptibility to cefuroxime. J Antimicrob Chemother 46: 215-221 [Abstract] [Full Text]  
  • Mimoz, O., Elhelali, N., Leotard, S., Jacolot, A., Laurent, F., Samii, K., Petitjean, O., Nordmann, P. (1999). Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum {beta}-lactamase-producing strain of Pseudomonas aeruginosa. J Antimicrob Chemother 44: 91-97 [Abstract] [Full Text]  
  • Georgopoulos, A., Buxbaum, A., Graninger, W. (1999). Efficacy of {beta}-lactam and inhibitor combinations in a diffusion chamber model in rabbits. J Antimicrob Chemother 43: 497-501 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»